Unitaid

Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria

Retrieved on: 
Monday, April 8, 2024
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, WHO, Ivermectin, Unitaid, IRD, Death, Malaria, IRSS, Vaccine

Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM.

Key Points: 
  • Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM.
  • If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission of malaria among vulnerable populations in high-transmission areas.
  • mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO® technology to fight malaria transmission.
  • Medincell is committed to the fight against the major global health threats, such as malaria that remains endemic in 85 countries representing 50% of the world's population.

The bio-detection market is expected to experience growth, reaching a value of USD 12.27 billion from 2022 to 2027- 17000 + Technavio

Retrieved on: 
Tuesday, January 23, 2024
Research, ROW, TB, Developed country, Infection, Unitaid, USD, Malaria, Speciality chemicals

Despite companies developing high-quality diagnostic technologies for chronic and infectious diseases, accessibility remains an issue in developing countries like India and China.

Key Points: 
  • Despite companies developing high-quality diagnostic technologies for chronic and infectious diseases, accessibility remains an issue in developing countries like India and China.
  • This drive encompasses various technologies such as biosensors, immunoassays, molecular diagnostics, microarray technology, and lab-on-a-chip devices, among others, to bolster bio-detection capabilities worldwide.
  • The observability platform market size is projected to increase by USD 1.17 billion, at a CAGR of 8.28% between 2023 and 2028.
  • The c ustomer engagement solutions market size is estimated to grow at a CAGR of 10.8% between 2022 and 2027.

Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost

Retrieved on: 
Tuesday, September 19, 2023
Partnership, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Bill & Melinda Gates Foundation, TB, Danaher, DHR, Infection, Research, International development, Danaher Corporation, Mark R. Dybul, Incidence, AIDS, Patient, Tuberculosis, United, Stop TB Partnership, USAID, NYSE, World Health Organization, Pharmaceutical industry, Video game, Unitaid, Malaria, Cepheid variable

Enables the Global Fund to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for TB at cost, with no profit to Danaher.

Key Points: 
  • Enables the Global Fund to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for TB at cost, with no profit to Danaher.
  • WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, today announced it will provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at Cepheid's cost of $7.97 each to the Global Fund to Fight AIDS, TB and Malaria ("the Global Fund") and to less-developed countries eligible for Cepheid's Global Access Program1 to support greater access to high-quality TB testing.
  • By reducing the price of Cepheid's Xpert® MTB/RIF Ultra test cartridge to $7.97, Danaher will be selling at its cost and will earn no profit.
  • The agreement significantly expands a longtime partnership between Cepheid - a Danaher operating company - and the Global Fund to improve access to testing where it matters most.

Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries

Retrieved on: 
Thursday, July 13, 2023
Biotechnology, AIDS, Hospitals, Health, Pharmaceutical, Penta, Unitaid, Monell Chemical Senses Center, Emtricitabine, Gilead Sciences, CHAI, Partnership, Sofosbuvir, Prevalence, HIV, European and Developing Countries Clinical Trials Partnership, Bill & Melinda Gates Foundation, TAF, SOF, DBM, Global health, Research, Medicine, Doctor of Philosophy, Bangladesh Technical Education Board, UNIVERSAL, EDCTP, Foundation for the National Institutes of Health, MD, Patient, Child, Viral, Developing country, Science, Mortality, Pediatrics, Technology transfer, Caregiver, Pharmaceutical industry, Vaccine

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.

Key Points: 
  • For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.
  • However, just over 50% of them are on antiretroviral treatment compared to 76% of adults living with HIV on treatment today.
  • Many LMICs have a high burden of mother-to-child transmission and the prevalence of HIV among children remains high.
  • “By developing medicine formulations that meet the needs of children, and by improving palatability, through these partnership, we have the ability to potentially increase adherence rates in children.

Global Latent Tuberculosis Infection Detection Market to 2030: Increasing Risk of Developing Active Tuberculosis Infection from LTBI Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 15, 2023
Health, Infectious Diseases, Research, TB, NHS, Risk, USD, Organization, HIV, UKHSA, Tuberculosis, Malaria, Government, Mark R. Dybul, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Diagnosis, QIAGEN, LTBI, Infection, Unitaid, Ageing, Vaccine, Pharmaceutical industry

Ltd

Key Points: 
  • Ltd
    The increased risk of developing active disease from latent tuberculosis infection (LTBI) coupled with the surge in the geriatric population globally is one of the major driving factors for the market growth.
  • In addition, rising awareness about TB detection and various government initiatives for effective diagnosis and screening of tuberculosis infection is another factor contributing to market expansion.
  • The market growth is fueled by the increase in the geriatric population across the globe.
  • Whereas the academic and research institutions segment is expected to exhibit the fastest CAGR during the projected period
    Chapter 3 Latent Tuberculosis Infection Detection Market Variables, Trends, & Scope

Innovation in Resistance Management: VECTRONTM T500, a New Vector Control Product, is Prequalified by the World Health Organization (WHO)

Retrieved on: 
Tuesday, March 14, 2023
Health, Chemicals, Plastics, Infectious Diseases, Manufacturing, Other Health, Research, Science, History, Public sector, Rotation, Insecticide, Bill, ISIN, PDP, Mark R. Dybul, Agency, Sale, Toxicity, PQ, USAID, IVCC, IRS, Tropical medicine, Aluminium, Multimedia, Malaria, IRAC, Swiss Agency for Development and Cooperation, Development, Liverpool School of Tropical Medicine, The Global Fund to Fight AIDS, Tuberculosis and Malaria, LSTM, Unitaid, Public, PPM, Mitsui Chemicals, Fine chemical, Vaccine

VECTRONTM T500 will support the rotation of insecticides in line with best practice insecticide resistance management, which is critical to preserve the long-term efficacy of vector control tools.

Key Points: 
  • VECTRONTM T500 will support the rotation of insecticides in line with best practice insecticide resistance management, which is critical to preserve the long-term efficacy of vector control tools.
  • VECTRONTM T500 has outstanding efficacy against malaria vector mosquitoes including strains and populations resistant to pyrethroids and some other insecticides.
  • Mitsui Chemicals Agro will launch VECTRONTM T500 in sub-Saharan African countries from 2023 in line with locally required conditions of use.
  • OZAWA says: “Mitsui Chemicals Agro is an R&D driven chemical company, that has been developing malaria vector control products to save human lives.

Unitaid and the Global Health Innovative Technology Fund strengthen ties to improve access to critical health tools

Retrieved on: 
Tuesday, February 28, 2023
ACT, Pillar, Access, United Nations, Climate change, HIV, Therapy, United Nations Development Programme, The Global Fund to Fight AIDS, Tuberculosis and Malaria, World Health Organization, Global health, Bill, PPP, UNDP, Organization, Hepatitis C, Partnership, HIV/AIDS, Research, Drug resistance, R, AIDS, Tuberculosis, Canine vector-borne disease, Tropical disease, Government of Japan, TB, Global Health Innovative Technology Fund, Multimedia, Bill & Melinda Gates Foundation, Cervical cancer, Vaccine, COVID-19, Pharmaceutical industry, Unitaid, Malaria, Wellcome

TOKYO and GENEVA, Feb. 28, 2023 /PRNewswire/ -- The Global Health Innovative Technology Fund (GHIT Fund) and global health agency Unitaid have signed a cooperation framework that aims to strengthen collaboration between the two agencies to increase cooperation between the Japanese research and development industry and the broader global health response.

Key Points: 
  • TOKYO and GENEVA, Feb. 28, 2023 /PRNewswire/ -- The Global Health Innovative Technology Fund (GHIT Fund) and global health agency Unitaid have signed a cooperation framework that aims to strengthen collaboration between the two agencies to increase cooperation between the Japanese research and development industry and the broader global health response.
  • This work will further efforts to ensure vulnerable and underserved populations have access to better health products and support progress towards universal health coverage.
  • "The recent COVID-19 pandemic has illustrated the importance of global collaboration in solving global problems," said Dr Philippe Duneton, Executive Director of Unitaid.
  • "Unitaid's reinforced partnership with the GHIT Fund will leverage ties with Japanese innovators who are addressing some of today's most pressing health challenges.

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
Thursday, October 20, 2022
Selection, Congress, Use, Medicine, Development, UICC, Non-communicable disease, Union, Essential medicines, Novartis, Sustainability, EOI, Patient, Private sector, Research, Access, MPP, Cancer, WHO, EML, Union for International Cancer Control, Nilotinib, World, WHO Model List of Essential Medicines, B cell, WHO Expert Committee on Leprosy, Agency, CML, SDC, Prognosis, Unitaid, Global Health, Coalition, Acute leukemia, Medicines Patent Pool, ATOM, Pharmaceutical industry, Medical imaging, Developing country

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory:

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
Thursday, October 20, 2022
Selection, Congress, Use, Medicine, Development, UICC, Non-communicable disease, Union, Essential medicines, Novartis, Sustainability, EOI, Patient, Private sector, Research, Access, MPP, Cancer, WHO, EML, Union for International Cancer Control, Nilotinib, World, WHO Model List of Essential Medicines, B cell, WHO Expert Committee on Leprosy, Agency, CML, SDC, Prognosis, Unitaid, Global Health, Coalition, Acute leukemia, Medicines Patent Pool, ATOM, Pharmaceutical industry, Medical imaging, Developing country

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory:

MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission

Retrieved on: 
Tuesday, September 13, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, Unitaid, Medicines Patent Pool, Malaria, MPP, Death, United Nations, Global Health, Compliance, Ivermectin, Foundation, Pharmaceutical industry, Vaccine

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of life-saving medicines for low- and middle-income countries.

Key Points: 
  • The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of life-saving medicines for low- and middle-income countries.
  • The licence agreement relates to a 3-Month active injectable formulation of ivermectin using Medincells BEPO technology to fight malaria transmission.
  • The licence agreement aims to ensure that the product be widely distributed in low- and middle-income countries if proven effective and safe.
  • MedinCell collaborate with tier one pharmaceuticals companies and foundations to improve Global Health through new therapeutic options.